One of the ways scientists hope to offer better treatments for vision loss is through gene therapy, where carefully selected genetic material is injected into the eyes to address mutations. Researchers have been left surprised by the effectiveness of an experimental form of this treatment, which involved an injection into one eyeball yet improved vision across both.
Gene therapies have the potential to treat all kinds of health conditions, ranging from cancer, to diabetes in dogs, to obesity and damaged spinal cords. One area where we're seeing some really exciting progress is in hereditary vision loss, with studies demonstrating the potential of gene therapy to treat color blindness, progressive retinal diseases and glaucoma, with some recently receiving approval from the FDA.
This latest study was conducted by scientists at the University of Cambridge, the University of Pittsburgh and Paris Institut de la Vision, and focuses on a form of inherited vision loss called Leber hereditary optic neuropathy (LHON). This affects around one in 30,000 people and usually occurs in young folks aged in their 20s and 30s, destroying their retinal ganglion cells and in turn the optic nerve. Once the condition takes hold, vision can deteriorate to the point where the subject is considered legally blind in just a matter of weeks, with recovery occurring in less than 20 percent of cases.
The majority of patients suffer from the same mutation affecting the MT-ND4 gene, so the researchers were hopeful of targeting this mutation as a way of improving treatment outcomes for sufferers of LHON. They trialed their gene therapy as part of a study involving 37 patients who had suffered vision loss in the preceding six to 12 months. This meant injecting a viral vector packed with a modified complementary DNA called rAAV2/2-ND4 into the vitreous cavity at the back of just one eye, with a sham treatment injected into the other eye.
We expected vision to improve in the eyes treated with the gene therapy vector only, says study author Dr Yu-Wai-Man. Rather unexpectedly, both eyes improved for 78 percent of patients in the trial following the same trajectory over two years of follow-up.
To investigate the reasons behind this unexpected outcome, the team studied the gene therapys effects in macaques, which have a similar vision system to humans. This enabled them to analyze the tissues from different parts of the eye to see how the viral vector DNA had spread. This provided evidence of interocular diffusion, with the viral vector DNA turning up in the retina, optic nerve and anterior segment of the untreated eye.
As someone who treats these young patients, I get very frustrated about the lack of effective therapies, says senior investigator Dr Sahel, from the University of Pittsburgh. These patients rapidly lose vision in the course of a few weeks to a couple of months. Our study provides a big hope for treating this blinding disease in young adults.
The research was published in the journal Science Translational Medicine.
Source: University of Cambridge
Original post:
Single gene therapy injection surprisingly boosts vision in both eyes - New Atlas
- Difference Between Ex Vivo and In Vivo Gene Therapy - December 30th, 2022
- Gene therapy: The Potential for Treating Type 1 Diabetes - Healthline - December 30th, 2022
- Gene therapy | Description, Uses, Examples, & Safety Issues - December 30th, 2022
- Cell and gene therapy: Biopharma portfolio strategy | McKinsey - December 30th, 2022
- History of Gene Therapy | Discovery and Evolution - December 30th, 2022
- What is Gene Therapy? | FDA - U.S. Food and Drug Administration - December 30th, 2022
- Gene Therapy Gel Offers New Hope Against Rare Blistering Disease - December 30th, 2022
- Fact Check-mRNA vaccines are distinct from gene therapy ... - Reuters - December 6th, 2022
- New Treatments for Retinitis Pigmentosa - American Academy of ... - December 6th, 2022
- The Era of One-Shot, Multimillion-Dollar Genetic Cures Is Here - WIRED - December 6th, 2022
- Greta Thunberg Says UN Climate Conference Is a Scam and She's Not Attending - November 4th, 2022
- This Deepfake AI Singing Dolly Parton's "Jolene" Is Worryingly Good - November 4th, 2022
- There's Something Strange About How These Stars Are Moving, Scientists Say - November 4th, 2022
- Manslaughter Case Has a Strange Twist: Tesla That Killed Couple Was on Autopilot - November 4th, 2022
- Twitter Working on Plan to Charge Users to Watch Videos - November 4th, 2022
- China Plans to Send Monkeys to Space Station to Have Sex With Each Other - November 4th, 2022
- Elon Musk Meeting With Advertisers, Begging Them Not to Leave Twitter - November 4th, 2022
- NASA Sets Launch Date for Mission to $10 Quintillion Asteroid - November 4th, 2022
- Scientists Found a Way to Control How High Mice Got on Cocaine - November 4th, 2022
- Cats May Be Tampering With Crime Scenes, Scientists Say - November 4th, 2022
- Scientists Use Actual Lunar Soil Sample to Create Rocket Fuel - November 4th, 2022
- Scientists Spot "Stripped, Pulsating Core" of Star Caused By Horrific Accident - November 4th, 2022
- US Gov to Crack Down on "Bossware" That Spies On Employees' Computers - November 4th, 2022
- AOC Says Her Twitter Account Broke After She Made Fun of Elon Musk - November 4th, 2022
- Hackers Just Took Down One of the World's Most Advanced Telescopes - November 4th, 2022
- Huge Drone Swarm to Form Giant Advertisement Over NYC Skyline - November 4th, 2022
- Chinese Spaceplane Releases Mystery Object Into Orbit - November 4th, 2022
- That "Research" About How Smartphones Are Causing Deformed Human Bodies Is SEO Spam, You Idiots - November 4th, 2022
- Jeff Bezos' Housekeeper Says She Had to Climb Out the Window to Use the Bathroom - November 4th, 2022
- Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership - PR Newswire - October 19th, 2022
- Gene therapy can make a real impact on global health but we need equitable access, say experts - World Economic Forum - October 19th, 2022
- Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022 - Managed Healthcare Executive - October 19th, 2022
- Carmine Gets Series A Funding to Develop Non-viral Gene Therapy |... - Cystic Fibrosis News Today - October 19th, 2022
- FDA Expands Oversight of Cell and Gene Therapies - Pharmaceutical Technology Magazine - October 19th, 2022
- Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals... - October 19th, 2022
- Survey Reveals Most People with Spinal Muscular Atrophy Using New Gene Therapies, Focused on Treatment Pipeline - PR Newswire - October 19th, 2022
- GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies - Yahoo Finance - October 19th, 2022
- Gamma Biosciences, Lonza Enter Cell and Gene Therapy Alliance - Contract Pharma - October 19th, 2022
- Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene... - October 19th, 2022
- Gene therapy Luxturna now reimbursed in Quebec for people with previously untreatable inherited vision loss(1) - Canada NewsWire - October 19th, 2022
- A sound approach for effective gene therapy delivery to brain - The Source - Washington University in St. Louis - Washington University in St. Louis - October 19th, 2022
- Worldwide AAV Vector Industry Report 2022 - by Type of Therapy, Type of Gene Delivery Method Used, Target Therapeutic Area, Application Area, Scale of... - October 19th, 2022
- LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission - BioSpace - October 19th, 2022
- Health News Roundup: Serum Institute to produce Ebola vaccine for use in Uganda outbreak; Eli Lilly to buy gene therapy company Akouos for $487... - October 19th, 2022
- New Pittsburgh biomanufacturing center to accelerate cell and gene therapy innovation - BioPharma-Reporter.com - August 30th, 2022
- Trinity team's new gene therapy shows promise for treating eye condition affecting millions across the globe - Ophthalmology Times - August 30th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022
- Defining the Impact of Gene Therapy - Managed Healthcare Executive - August 30th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022
- India Gene Therapy Market Research Report 2022: Prospects, Trends, Market Size and Forecasts to 2028 - ResearchAndMarkets.com - Business Wire - August 30th, 2022
- Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights - PR Newswire - August 30th, 2022
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022
- Porton Advanced and Kun Tuo Announce Strategic Partnership to Deepen Gene and Cell Therapy CDMO and Clinical Research Services - PR Newswire - August 30th, 2022
- Gene therapies for lung cancer identified by international team of scientists - Labiotech.eu - August 30th, 2022
- BioForest is Breaking Out with Innovation, Talent and Investment - BioSpace - August 30th, 2022
- Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio - Yahoo Finance - August 30th, 2022
- An international team sets out to cure genetic heart diseases with one shot - Freethink - August 30th, 2022
- What is the difference between sickle cells and healthy RBCs? - Medical News Today - August 30th, 2022
- Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials - HDBuzz - August 30th, 2022
- Cell therapy weekly: Kyverna Therapeutics appoints new Senior Vice President - RegMedNet - August 30th, 2022
- GICELL Announces Research Collaboration with HK inno.N for next-generation CAR-NK therapy - BioSpace - August 30th, 2022
- Document: Big Pharma exec: COVID shots are 'gene therapy' - July 8th, 2022
- Gene & Cell Therapy FAQs | ASGCT - American Society of Gene & Cell ... - July 8th, 2022
- Gene therapy - Mayo Clinic - July 8th, 2022
- FDA approves novel gene therapy to treat patients with a rare form of ... - July 8th, 2022
- Adeno-Associated Virus (AAV) as a Vector for Gene Therapy - July 8th, 2022
- Gene therapy: Where the action is for retinal diseases - Modern Retina - July 8th, 2022
- Adverum cuts jobs, restructures to give eye gene therapy another shot - BioPharma Dive - July 8th, 2022
- EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS - Labiotech.eu - July 8th, 2022
- Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA - Business Wire - July 8th, 2022
- TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022" - PR Newswire - July 8th, 2022
- AAVIATE: Gene therapy via suprachoroidal drug delivery may lower treatment burden for patients with AMD - Modern Retina - July 8th, 2022
- Gene Therapy Market is Expected to Grow Revenue up to USD 20 Billion by 2028 Know More with Infinium Global Research - Digital Journal - July 8th, 2022
- Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This Week - The Motley Fool - July 8th, 2022
- PROMISING STEM CELL THERAPY IN THE MANAGEMENT OF HIV & AIDS | BTT - Dove Medical Press - July 8th, 2022
- Sio Gene Therapies Inc. (NASDAQ:SIOX) Short Interest Up 33.4% in June - Defense World - July 8th, 2022
- Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy -... - July 8th, 2022
- A look at prospects for the US gene therapy industry - BioPharma-Reporter.com - December 27th, 2021
- Taysha Gene Therapies Added to the ICE Biotechnology Index - BioSpace - December 27th, 2021